Status:
COMPLETED
Transitioning From Cyclosporine to Alefacept in Psoriasis
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Collaborating Sponsors:
Biogen
Conditions:
Psoriasis
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.
Detailed Description
The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept. Patients in the study are well controlled on cyclosporine and desire to sw...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Adult psoriasis patients (18 to 80 years old), who are well controlled on cyclosporine (Static PGA score of mild, minimal or clear) and who need or desire to stop cyclosporine and start alefacept.
- Exclusion Criteria
- CD4 \<400
- Active infection (other than trivial URI, etc.)
- History of AIDS or Hepatitis B, C
- Inability to understand consent or comply with study requirements
- Pregnancy or Lactation
- History of heart or liver disease
Exclusion
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00143806
Start Date
October 1 2003
End Date
May 1 2007
Last Update
January 5 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UMDNJ Clinical Research Center
New Brunswick, New Jersey, United States, 08903